


MAXIM.078A



RECEIVED

APR 30 2002

*Handwritten notes:*  
L.H. of time  
J. mas  
PATENT  
#9/A VE

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. Hellstrand, et al.

Appl. No. : 09/616,622

Filed : July 14, 2000

For : **ACTIVATION AND  
PROTECTION OF  
CYTOTOXIC  
LYMPHOCYTES USING A  
REACTIVE OXYGEN  
METABOLITE INHIBITOR**

Examiner : G.R. Ewoldt

) Group Art Unit 1644

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with the  
) United States Postal Service as first-class mail in  
) an envelope addressed to: United States Patent  
) and Trademark Office, P.O. Box 2327,  
) Arlington, VA 22202, on

) April 22, 2002

) (Date)

) *[Signature]*  
) James J. Mullen III, Ph.D., Reg. No. 44,957

**COPY OF PAPERS  
ORIGINALLY FILED**

AMENDMENT AND RESPONSE

United States Patent and Trademark Office  
P.O. Box 2327, Arlington, VA 22202

Dear Sir:

This is in response to the Office Action mailed November 20, 2001 (Paper No. 8) for the above-referenced patent application. Reconsideration of the application in view of the amendments and remarks below is respectfully requested.

**IN THE SPECIFICATION**

Please amend the sentence on page 7, beginning at line 9 and ending at line 12 as follows:

*W*  
In one embodiment the invention relates to a method comprising identifying a patient in need of enhanced cytotoxic lymphocyte activity, and administering to the patient an amount of diphenylene iodonium (DPI) effective to activate and protect cytotoxic lymphocyte function in the presence of MO.

04/26/2002 HNOOR1 00000041 09616622

01 FC:116

400.00 DP